People with diabetes regularly receiving insulin in the relevant year

Description

This indicator shows the number and percent of people with diabetes dispensed insulin regularly. Regular use was defined as insulin dispensed in three or more quarters in a year.

Rationale

Understanding the reasons behind variations in insulin is important as it can give some insights into differences in the quality of care received by people with diabetes. It helps to develop strategies that promote effective diabetes management, ensure equitable access to insulin therapy when needed, and enhance patient outcomes. Some reasons for variation in insulin usage include diabetes type, patient acceptance, adherence, and physician preferences.

Measure set
Health areas and conditions
Measure type
Count
Percent
Numerator

People with diabetes dispensed insulin in three or four quarters in the relevant year.

Numerator detail

Medications: 119201 & 119202 Insulin lispro

164801 & 164803 Insulin neutral

164903 & 164904 Insulin isophane

165502 Inj crystalline human 100 u per ml

165501 Inj human 100 u per ml

378325, 378326 & 378327 Insulin aspart

385725, 385726 & 385727 Insulin glargine

388225 & 388226 Insulin lispro with insulin lispro protamine

390825, 390826 & 390827 Insulin glulisine

398227 Insulin aspart with insulin aspart protamine

630002 & 630003 Insulin isophane with insulin neutral 

Numerator exclusions
  • People who died during the year
  • People not enrolled in a PHO
Denominator

Count of distinct master NHIs identified as having diabetes on the VDR.

Disaggregation

For single map analysis: By year (2018‒22), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other) and Health New Zealand district of domicile. 

For PHO analysis: By year (2022), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other), PHO most recently enrolled with (for the relevant year), PHO group (small, medium, medium‒large and large).

Notes

Exclusions 

  • People who died during the year
  • People not enrolled in a PHO

See technical document for details

Measure methodology last updated
June 2024
Reference period
2018-2022